Surgery in mesothelioma
Surgery in mesothelioma
Advances and perspectives on biomarkers
Biomarker analyses in emerging data from PI3K/AKT/mTOR programme clinical trials
Integrating breast cancer genomics and proteomics
Genetic and clinical factors best for predicting late recurrence in oestrogen receptor positive breast cancer
CD4 T cells in extensively inflitrated breast cancer signal organised immune response and predict survival
How do we design trials that improve outcome?
Breast cancer heterogeneity no barrier to predictive testing
Single cell sequencing techniques in early and late breast cancer
The future of PI3K/AKT/mTOR inhibitors in breast cancer
Multitarget FISH testing in lung cancer
Mesothelioma and the tumour suppressor gene, NF2